Published in Vaccine Weekly, November 22nd, 2006
The first study of its kind, Tuberculosis Vaccines: The Case for Investment analyzes the demand for a tuberculosis vaccine and the potential return on industry investment, while demonstrating that a new TB vaccine would have tremendous public health impact.
"This study supports - with quantitative analysis - the premise that products that address a key problem of global health can also generate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.